Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) has taken a significant step toward expanding its oncology pipeline by entering into a non-binding letter of intent (LOI) with Ifowonco Informatics Incorporated. The LOI is the initial phase in negotiating a definitive agreement that would grant Onco an exclusive option on Ifowonco's proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (LAG-3). This move underscores Onco's commitment to advancing next-generation cancer therapies.
The proposed collaboration aims to combine Ifowonco's oral small-molecule immune checkpoint technology with Onco-Innovations' expertise in DNA damage response (DDR) therapeutics, translational oncology, and clinical development. The companies believe that the combination of DDR inhibition and LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. This synergistic approach is particularly promising because DDR inhibitors can increase the immunogenicity of tumours, making them more susceptible to immune attack, while LAG-3 blockade helps sustain T-cell activity.
Ifowonco's program focuses on developing orally available small-molecule LAG-3 inhibitors, a departure from currently approved LAG-3 therapies that are administered intravenously as monoclonal antibodies. Oral inhibitors offer the potential for improved patient convenience, lower healthcare costs, and more flexible dosing regimens. The companies intend to evaluate the LAG-3 program independently and, where supported by preclinical findings, explore its potential use alongside DDR-based therapeutic approaches, including Onco-Innovations' ONC010 program.
Thomas O'Shaughnessy, CEO of Onco-Innovations, expressed optimism about the potential agreement, stating that it could position the company "at the intersection of precision oncology and next-generation cancer immunotherapy." This strategic move aligns with Onco's mission to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has previously secured an exclusive worldwide license to patented technology that targets solid tumours, and this new initiative could further strengthen its portfolio.
The LOI represents a critical step in Onco-Innovations' growth strategy, as it seeks to diversify its pipeline and address unmet medical needs in oncology. By leveraging Ifowonco's proprietary technology, Onco aims to accelerate the development of novel combination therapies that could improve outcomes for cancer patients. The potential collaboration highlights the growing interest in combining different therapeutic modalities to overcome resistance mechanisms and enhance anti-tumor immunity.
For investors, this development signals Onco-Innovations' proactive approach to building a robust oncology franchise. The company's focus on DDR therapeutics, which are being explored in various clinical settings, combined with the addition of an oral LAG-3 inhibitor, could provide a competitive edge in the rapidly evolving field of cancer immunotherapy. As the agreement progresses, further details on the terms and development plans are expected to emerge.
The full press release can be viewed at https://ibn.fm/E63Ne. For the latest news and updates on Onco-Innovations, visit the company's newsroom at https://ibn.fm/ONNVF.
